Goldman Sachs
NBIX icon

Goldman Sachs’s Neurocrine Biosciences NBIX Stock Holding History

Goldman Sachs’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,200
Closed -$402K – 6549
2025
Q2 		$402K Buy
+3,200
New +$367K ﹤0.01% 5287
2022
Q1 		– Sell
-30,000
Closed -$2.56M – 6794
2021
Q4 		$2.56M Buy
+30,000
New +$2.76M ﹤0.01% 4032
2020
Q2 		– Sell
-32,700
Closed -$2.83M – 5389
2020
Q1 		$2.83M Buy
+32,700
New +$3.2M ﹤0.01% 3071
2017
Q4 		– Sell
-92,500
Closed -$5.67M – 6545
2017
Q3 		$5.67M Buy
+92,500
New +$4.88M ﹤0.01% 3029
2017
Q1 		– Sell
-25,000
Closed -$968K – 6915
2016
Q4 		$968K Buy
+25,000
New +$1.13M ﹤0.01% 4485
2016
Q3 		– Sell
-203,100
Closed -$9.23M – 7126
2016
Q2 		$9.23M Buy
203,100
+163,800
+417% +$7.54M ﹤0.01% 2378
2016
Q1 		$1.55M Sell
39,300
-51,100
-57% -$2.03M ﹤0.01% 3707
2015
Q4 		$5.11M Sell
90,400
-215,000
-70% -$10.9M ﹤0.01% 2805
2015
Q3 		$12.2M Buy
305,400
+256,500
+525% +$12.4M ﹤0.01% 2104
2015
Q2 		$2.33M Sell
48,900
-100
-0.2% -$4.24K ﹤0.01% 3687
2015
Q1 		$1.95M Buy
+49,000
New +$1.75M ﹤0.01% 3808
2014
Q4 		– Sell
-379,500
Closed -$5.95M – 7244
2014
Q3 		$5.95M Buy
+379,500
New +$5.67M ﹤0.01% 2839
2014
Q2 		– Sell
-94,900
Closed -$1.53M – 7082
2014
Q1 		$1.53M Buy
+94,900
New +$1.62M ﹤0.01% 4251

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs's NBIX Position: Q2 2026 in Review

Goldman Sachs increased its Neurocrine Biosciences (NBIX) stake by 81% in Q2 2026, buying an estimated $41.9M and bringing the position to 631,892 shares worth $106M. The position accounts for 0.01% of the portfolio, ranked #1178.

Goldman Sachs first reported a position in NBIX in Q2 2013 and has held it in 53 quarters since. The position peaked at $166M in Q4 2017. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Goldman Sachs held 631,892 shares of Neurocrine Biosciences worth $106M as of Q2 2026.
  • Goldman Sachs bought 282,713 Neurocrine Biosciences shares in Q2 2026, an estimated $41.9M.
  • Neurocrine Biosciences made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1178 holding.
  • Goldman Sachs first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 53 quarters since.
  • Goldman Sachs's Neurocrine Biosciences position peaked at $166M in Q4 2017.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.